| Coeptis Therapeutics, a biotech firm, is making bold moves in the cell therapy market, valued at a hefty $60.67 billion. Yet, financial hurdles cast long shadows over their ambitious plans. Their shares hint at potential, but the path to success is uncertain. Will they revolutionize cancer treatment as they promise, or crumble under the weight of their aspirations? While that question might be something investors care about, it doesn't really impact short-term traders. All they want to know is if the stock has momentum and a strong enough catalyst to push its stock price higher. So what about Coeptis, can it run from here? Coeptis Therapeutics Holdings (NASD: COEP) - 1-month trading range: $1.15 - $2.19
- Typical average daily volume: 378,410
- Float: ~ 10.7 million
Coeptis Therapeutics Business Coeptis Therapeutics is an innovative biotechnology company striving to revolutionize how we combat diseases, particularly cancers, through cutting-edge cell therapies. The cornerstone of their work is the GEAR™ cell therapy platform, which uses modified natural killer (NK) cells, crucial players in the immune system's defense against tumors. Their proprietary product, CD38-GEAR-NK, is being developed to treat multiple myeloma, a type of cancer that forms in a white blood cell called a plasma cell. This breakthrough treatment aims to optimize NK cells to be combined with targeted antibodies, thus enhancing their ability to detect and destroy cancerous cells. The CD38-GEAR-NK project is supplemented by their diagnostic platform, CD38-Diagnostic, a tool being developed to analyze if cancer patients might benefit from therapies targeting CD38, a protein expressed in many cancers. This personalized approach ensures the right treatment gets to the right patient, increasing effectiveness and minimizing potential side effects. In partnership with the University of Pittsburgh, Coeptis is exploring more potentially groundbreaking technologies, like CAR T therapies, another type of cell-based treatment that modifies patients' T-cells to recognize better and fight cancer. 
Source: Coeptis Therapeutics Their SNAP-CAR technology offers the potential to target multiple types of tumors, broadening the impact of this novel approach. Coeptis is also working on integrating assets from Deverra Therapeutics, including two IND applications and two Phase 1 clinical trials studying allogenic cell therapies developed from NK cells. These therapies could represent transformative treatments for diseases like Acute Myeloid Leukemia and Acute Respiratory Diseases. The company has been busy over the last few months. Copetis secured exclusive rights to negotiate to acquire a transformational cell therapy platform to enable potent combinatorial immuno-oncology treatment strategies in late March of this year. In April, it signed an agreement to acquire the allogeneic Immuno-oncology NK platform in Phase 1 clinical trials from Devrra Therapeutics. Coepits Therapeutics Snap-CAR technology platform for programmable antigen targeting was featured in a peer-reviewed article in Nature Communications last month. Financials 
Source: Stockanlysis.com Starting off, we've hit a major snag. COEP revenue clocked in at a big, fat zero in the TTM period and 2022. Talk about a downhill plunge from the $0.08 million in 2021 and the $0.03 million in 2020. Let's talk about the big OI, operating income. It's been stuck in the red, and it's not getting any better. TTM shows a staggering loss of -$24.93 million. Sure, it's less of a shocker than the -$34.2 million drop in 2022, but it's still worse than the -$14.05 million in 2021 and the -$6.71 million in 2020. A little less painful, but we're still nursing a financial bruise. Now onto EPS or Earnings Per Share. TTM shows a -2.51, a smidge better than the -2.63 in 2022. But let's not start the celebration just yet. It's far from the -1.23 in 2021 and a mile away from -0.51 in 2020. This EPS trend is like a bungee jump without the bounce back up. Shifting gears to outstanding shares. These have been on a wild ride, stabilizing between 2022 and TTM at 20 million. We had a spike from 2 million in 2019 to a dizzying 18 million in 2020. Seems like the company's been shaking the fundraising tree or messing around with capital structure. Bringing up the rear, operating expenses. They're sitting at $24.93 million in the TTM period, which is an improvement from the whopping $34.2 million in 2022. But the spending's still way up compared to the $14.12 million in 2021 and $5.78 million in 2020. Sure, there's been a bit of belt-tightening, but it's like fighting a forest fire with a garden hose. All in all, this company's navigating a financial storm. Revenue's disappeared, losses are snowballing, and despite minor improvements in EPS and expenses, the forecast's not looking too bright. Luckily, fundamentals don't factor much when you're short-term trading. Promoter Activity I started receiving emails about this company from one promoter starting on May 30th. And by the looks of my email inbox, they're back for round two. Here are some of the reasons why investors should care about COEP: - Strong Price Action: COEP has been trending higher, with the potential to reach $2.00 per share. Additionally, it's trading above its 50-day simple moving average (SMA) and other exponential moving averages (EMAs), showing upward momentum
- Low Float: According to Yahoo Finance, COEP has fewer than 13 million shares available in its float. This low float can lead to high volatility, suggesting the potential for sharp price movements and short squeezes.
- Disruptive Potential in Growing Market: COEP is a potential disruptor in the booming cell therapy market, which is projected to reach $60.67 billion by 2030. It is developing innovative cell therapy platforms for cancer treatment.
- Strategic Collaborations and Licenses: The company has strategic partnerships with renowned institutions such as the University of Pittsburgh and VyGen-Bio, and licenses to potentially game-changing technologies like SNAP CAR T cell therapy.
- Possible Game-Changing Acquisition: COEP has agreed to acquire a novel allogeneic immuno-oncology NK platform from Deverra Therapeutics. This acquisition, which includes two clinical-stage assets and preclinical programs, could significantly expand COEP's portfolio and open new therapeutic avenues.
The promoter effectively highlighted COEP's growth potential, strategic collaborations, and disruptive technologies in the expanding cell therapy market, making a compelling case for the stock. They were hired on May 24, 2023 and will continue promoting COEP until July 5, 2023. They're receiving $200,000 for this awareness campaign. Straight to the Facts COEP is in a relatively hot sector. More importantly, Less then one year ago this stock was trading above $21 per share. It's down nearly 92% from those highs. It's pretty cheap right now…and the float is relatively low. With the right pump, this could make a run. Keep an eye out on it, trading volume was above average on Tuesday, trading 1.2 million shares vs. its 378k average. Something could be brewing. Always at your service, Baron Von Stocks | 
Post a Comment
Post a Comment